Epilepsy Impact Scale

Questionnaire Development for a Comprehensive Scale to Measure the Impact of Epilepsy on Life.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01833234

Enrollment

Registered

2013-04-16

Start date

2012-07-31

Completion date

2014-09-30

Last updated

2016-04-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epilepsy

Keywords

epilepsy, quality of life, seizure severity, antiepileptic drug side effects, questionnaire, patient reported outcomes

Brief summary

The investigators are developing a questionnaire that can quickly measure the impact that epilepsy has on a person's life. This questionnaire will be useful in following whether the impact of epilepsy increases, decreases or stays the same over time. The results also may point out areas that would benefit from discussion or attention in visits with your doctor.

Detailed description

The investigators have used a set of broad open-ended questions about the impact of epilepsy on a person's life to formulate a long list of questions to characterize the impact the seizures, medications, and comorbidities that you are having. In the future, this will be boiled down to a short list of questions.

Interventions

OTHERInterviews and questionnaires

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Age 18 or more. 2. Patient has had at least 1 seizure in the past 365 days. 3. Patient can speak and understand English.

Exclusion criteria

1. Patients suspected of having one of the imitators of epilepsy, for example, syncope, sleep disorder, psychogenic nonepileptic seizures, will be excluded, even if they also have epileptic seizures. 2. Patients unwilling to spend the time doing the questionnaire.

Design outcomes

Primary

Measure	Time frame
Validation of a concise question set	Up to 1 year for question set validation, data presentation within up to 1.5 years

Secondary

Measure	Time frame	Description
Correlation of subscales	Up to 1.5 years	Correlation of subscales of the study questionnaire with previously validated scales, including QoLiE-39, NHS Seizure Severity Scale, Liverpool side effects scale, Beck Depression Index

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026